Bolt Biotherapeutics (BOLT) Operating Income (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Operating Income of -$7.6 million for Q1 2026, down 7.28% sequentially from -$7.1 million in Q4 2025, and up 37.26% YoY from -$5.5 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Operating Income (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Operating Income for 7 years, with the latest figure at -$7.6 million in Q1 2026.
- Quarterly Operating Income rose 37.26% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.6 million (up 53.58% YoY) and the FY2025 annual result came in at -$36.1 million, up 50.56% from the prior year.
- Operating Income fell to -$7.6 million in Q1 2026 per BOLT's latest filing, from -$7.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$7.1 million in Q4 2025 and troughed at -$23.9 million in Q1 2022.
- A 5-year average of -$16.7 million and a median of -$18.2 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income retreated 29.58% in 2022, then soared 59.24% in 2025.
- Over 5 years, Operating Income stood at -$21.0 million in 2022, then gained by 6.06% to -$19.8 million in 2023, then gained by 14.42% to -$16.9 million in 2024, then surged by 58.12% to -$7.1 million in 2025, then retreated by 7.28% to -$7.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$7.6 million, -$7.1 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | -8.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.37 Mn |
| Mar 31, 2026 | -7.60 Mn |
| Dec 31, 2025 | -7.09 Mn |
| Sep 30, 2025 | -7.70 Mn |
| Jun 30, 2025 | -9.21 Mn |
| Mar 31, 2025 | -12.12 Mn |
| Dec 31, 2024 | -16.92 Mn |
| Sep 30, 2024 | -16.44 Mn |
| Jun 30, 2024 | -22.60 Mn |
| Mar 31, 2024 | -17.09 Mn |
| Dec 31, 2023 | -19.77 Mn |
| Sep 30, 2023 | -18.18 Mn |
| Jun 30, 2023 | -19.83 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -21.04 Mn |
| Sep 30, 2022 | -22.35 Mn |
| Jun 30, 2022 | -23.06 Mn |
| Mar 31, 2022 | -23.88 Mn |
| Dec 31, 2021 | -27.08 Mn |
| Sep 30, 2021 | -23.53 Mn |